290 related articles for article (PubMed ID: 33220601)
1. The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities.
Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Sheikholeslami SA; Salari S; Bashash D
Crit Rev Oncol Hematol; 2021 Jan; 157():103160. PubMed ID: 33220601
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles.
Mahdavi Gorabi A; Sadat Ravari M; Sanaei MJ; Davaran S; Kesharwani P; Sahebkar A
Int Immunopharmacol; 2022 Dec; 113(Pt A):109300. PubMed ID: 36252486
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
5. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
[TBL] [Abstract][Full Text] [Related]
6. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Development of Immune Checkpoint Inhibitors.
Wang J; Yang T; Xu J
Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
9. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
Deng H; Zhang Z
J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Resistance to Checkpoint Blockade Therapy.
Shi H; Lan J; Yang J
Adv Exp Med Biol; 2020; 1248():83-117. PubMed ID: 32185708
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Shen H; Yang ES; Conry M; Fiveash J; Contreras C; Bonner JA; Shi LZ
Genes Dis; 2019 Sep; 6(3):232-246. PubMed ID: 32042863
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors.
Wang J; Zhu N; Su X; Yang R
Cancer Lett; 2024 Feb; 582():216582. PubMed ID: 38065401
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
18. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
19. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
20. Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.
Li Y; Wang S; Lin M; Hou C; Li C; Li G
Front Med; 2022 Jun; 16(3):307-321. PubMed ID: 35648368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]